SCHEMBL3015791

SCHEMBL3015791

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C)c(C)cc(C)c4C)CC3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPK1 P28482 1/20 0.40
DNM1L O00429 2/20 0.38
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013060 0.91 NPSR1 (0.43) MEN1KMT2ALMNAMAPTGAA
SCHEMBL2998652 0.91 MEN1 (0.47) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3004183 0.90 MEN1 (0.42) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3653425 0.90 MAPT (0.39) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3022608 0.90 KMT2A (0.45) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3011032 0.89 KMT2A (0.46) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3007191 0.89 MAPT (0.49) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3025280 0.88 PKM (0.45) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3017922 0.88 MAPT (0.41) MEN1KMT2AL3MBTL1LMNAMAPT
SCHEMBL3018025 0.88 KMT2A (0.45) MEN1KMT2AL3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.